Literature DB >> 19346954

The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York.

Patricia K Duffner1, Verne S Caviness, Richard W Erbe, Marc C Patterson, Kirk R Schultz, David A Wenger, Chester Whitley.   

Abstract

Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive disorder of white matter resulting from deficiency of galactosylceramide beta-galactosidase (GALC) and the consequent accumulation of galactosylceramide and psychosine. Although most patients present within the first 6 months of life, i.e., the early infantile or "classic" phenotype, others present later in life including in adolescence and adulthood. The only available treatment for infants with early infantile Krabbe disease is hematopoietic cell transplantation (HCT), typically using umbilical cord blood. Although transplanted children are far better neurologically than they would have been had they followed the typical fulminant course of early infantile Krabbe disease, anecdotal reports have surfaced suggesting that the majority of presymptomatic children transplanted for Krabbe disease have developed motor and language deterioration. The cause and extent of the deterioration is unknown at this time. With the advent of universal newborn screening for Krabbe disease in New York State and the projected start of screening in Illinois in 2010, understanding the outcome of treatment becomes of paramount importance. Thus, the purpose of this workshop was to bring together child neurologists, geneticists, neurodevelopmental pediatricians, transplanters, neuroradiologists, neurophysiologists, developmental neurobiologists, neuroscientists, and newborn screeners to review the results of the transplantation experience in humans and animals and, if neurologic deterioration was confirmed, develop possible explanations as to causation. This workshop was the first attempt at a multicenter crossdiscipline evaluation of the results of HCT for Krabbe disease. A broad range of individuals participated, including clinicians, academicians, and authorities from the National Institutes of Health, American College of Medical Genetics, and Department of Health and Human Services.

Entities:  

Mesh:

Year:  2009        PMID: 19346954     DOI: 10.1097/GIM.0b013e3181a16e04

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  37 in total

Review 1.  Newborn screening for neuropathic lysosomal storage disorders.

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease.

Authors:  Cynthia B Ripoll; Mette Flaat; Jessica Klopf-Eiermann; Jeanne M Fisher-Perkins; Cynthia B Trygg; Brittni A Scruggs; Marjorie L McCants; Helen Paige Leonard; Amy F Lin; Shijia Zhang; Michelle E Eagle; Xavier Alvarez; Yu Teh Li; Su Chen Li; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells       Date:  2011-01       Impact factor: 6.277

Review 3.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 4.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 5.  Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations.

Authors:  Keri R Maher; Andrew M Yeager
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

6.  Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease.

Authors:  Dae Song Jang; Wenjuan Ye; Tian Guimei; Melani Solomon; Noel Southall; Xin Hu; Juan Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

7.  Successful cord blood transplantation in a 42-day-old boy with infantile Krabbe disease.

Authors:  Hiroshi Yagasaki; Maiko Kato; Mika Ishige; Hiroyuki Shichino; Motoaki Chin; Hideo Mugishima
Journal:  Int J Hematol       Date:  2011-04-12       Impact factor: 2.490

8.  Disease specific therapies in leukodystrophies and leukoencephalopathies.

Authors:  Guy Helman; Keith Van Haren; Joshua L Bonkowsky; Genevieve Bernard; Amy Pizzino; Nancy Braverman; Dean Suhr; Marc C Patterson; S Ali Fatemi; Jeff Leonard; Marjo S van der Knaap; Stephen A Back; Stephen Damiani; Steven A Goldman; Asako Takanohashi; Magdalena Petryniak; David Rowitch; Albee Messing; Lawrence Wrabetz; Raphael Schiffmann; Florian Eichler; Maria L Escolar; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2015-02-07       Impact factor: 4.797

9.  Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease.

Authors:  Jameson J Ribbens; Ann B Moser; Walter C Hubbard; Ernesto R Bongarzone; Gustavo H B Maegawa
Journal:  Mol Genet Metab       Date:  2013-09-21       Impact factor: 4.797

10.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.